Abstract
The Food and Drug Administration (FDA) is a large regulatory agency that monitors everything from food, tobacco, and veterinary medicine to pharmaceutical drugs and medical devices. The Mission statement of the CDRH, one of the Centers of the FDA, in its most succinct form is to protect and promote public health. This is accomplished through timely and continued access to safe, effective, and high quality medical devices. This paper aims to review the overarching principles of the Agency’s review process for cardiac devices as well as highlight some of the newer programs that FDA has engaged in to facilitate innovation, device development, research, and timely market approval.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Information sheet guidance for IRBs, clinical investigators, and sponsors. http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM127067.pdf
Requests for feedback on medical device submissions: the pre-submission program and meetings with Food and Drug Administration staff. http://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm311176.pdf
Code of federal regulations Title 21, Food and drugs, Chapter 9, Subchapter X, section 396. Practice of medicine. 21 CFR 396(9)(x).
FDA decisions for investigational device exemption clinical investigations. http://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm279107.pdf
Code of federal regulations. Title 21. Part 812.2(c).
IDE Basics, Soma Kalb Nov 4, 2014. http://www.fda.gov/downloads/Training/CDRHLearn/UCM421763.pdf
Code of federal regulations, Title 21 Food and drugs, Volume 8, Chapter I, Subchapter H, Part 812. Investigational device exemptions.
Code of federal regulations. Title 21. CFR 812.3(m).
Code of federal regulations. Title 21. CFR 812.2(b).
Code of federal regulations. Title 21. Food and drugs, Chapter I, Subchapter H, part 814. Premarket approval of medical devices. Humanitarian use devices.
Guidance for HDE holders, institutional review boards (IRBs), clinical investigators, and Food and Drug Administration staff. http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm110203.pdf
CDRH video broadcast January 20, 2010. http://inside.fda.gov:9003/cdrh/officeofthedirector/ucm198536.htm
Medical device innovation initiative white paper February 2011. http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDRH/CDRHInnovation/ucm242067.htm
2014–2015 strategic priorities, CDRH, FDA, HHS. http://www.fda.gov/downloads/aboutfda/centersoffices/officeofmedicalproductsandtobacco/cdrh/cdrhvisionandmission/ucm384576.pdf
Investigational device exemptions (IDEs) for early feasibility medical device clinical studies, including certain first in human (FIH) studies. http://www.fda.gov/downloads/medicaldevices/deviceregulationand%20guidance/guidancedocuments/ucm279103.pdf
Expedited access for premarket approval and de novo medical devices intended for unmet medical need for life threatening or irreversibly debilitating diseases or conditions. http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM393978.pdf
http://mdic.org/ctir/ [website for Medical Device Innovation Consortium, Clinical Trial Innovation and Reform]
De novo classification process (evaluation of automatic class III designation). http://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm273903.pdf
Factors to consider when making benefit-risk determinations in medical device premarket approval and de novo classifications. http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM296379.pdf
Balancing premarket and postmarket data collection for devices subject to premarket approval. http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-meddev-gen/documents/document/ucm393994.pdf
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Selzman, K.A., Fellman, M., Farb, A. et al. New technology in electrophysiology: FDA process and perspective. J Interv Card Electrophysiol 47, 11–18 (2016). https://doi.org/10.1007/s10840-016-0127-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10840-016-0127-4